Troriluzole in Adult Participants With Spinocerebellar Ataxia
Key facts
- Who runs it
- Biohaven Pharmaceuticals, Inc.
- Where
- Ann Arbor, Atlanta, Aurora, Boston, Chicago, Durham, Gainesville, Houston, Jacksonville, Long Beach, Los Angeles, Lutherville, New York, Philadelphia, Phoenix, Rolling Meadows, San Francisco, Seattle, and Tampa, United StatesSee the 21 sitesAlso in 1 other country, 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 299 people enrolled
- Started
- 8 Mar 2019
- Ended
- 3 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- troriluzole
- Placebo
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Participants with a known or suspected diagnosis of the following specific hereditary ataxias: SCA1, SCA2, SCA3, SCA6, SCA7, SCA8 and SCA10; A participant should have a confirmed genotypic diagnosis from a Clinical Laboratory Improvement Amendments (CLIA) certified lab (can produce test results); or,; A participant has a family member that has a confirmed genotypic diagnosis from a CLIA certified lab (can produce test results) and must be willing to undergo genetic testing to confirm underlying SCA diagnosis; or,; A participant has a confirmed genotypic diagnosis from a lab that is not CLIA certified and must be willing to undergo genetic testing to confirm underlying SCA diagnosis; or,; A participant has clinical evidence that supports diagnosis of one of the aforementioned SCA genotypes but does not have producible test results from a CLIA certified lab from either a family member or for his or herself and the participant must be willing to undergo such testing to confirm the SCA diagnosis (in this case, site must wait for results of genotypic testing prior to randomization)
- Ability to ambulate 8 meters without human assistance (canes and other devices allowed)
- Screening Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) total score ≥3
- Score of ≥1 on gait subsection of the f-SARA
- Determined by the investigator to be medically stable at Baseline/randomization as assessed by medical history, physical examination, laboratory test results, and electrocardiogram testing
Who cannot take part
- Any medical condition other than one of the hereditary ataxias specified in the inclusion criteria that could predominantly explain or contribute significantly to the participants' symptoms of ataxia
- Participants should be excluded at screening or baseline if medical conditions have arisen or there is a change in disease status that could confound the ability of the SARA to accurately reflect changes in ataxia severity
- Active liver disease or a history of hepatic intolerance to medications that in the investigator's judgment, is medically significant
- A ≥ 2-point difference on the Modified Functional SARA score between screening and baseline
- Mini Mental State Exam (MMSE) score <24
- A prominent spasticity or dystonia that, in the opinion of the investigator, will compromise the ability of the SARA instrument to assess underlying ataxia severity
- A score of 4 on any individual item (Items 1-4) of the f-SARA
Where in United States
Also in 1 other country, 2 sites
- University of MichiganAnn Arbor, United States
- EmoryAtlanta, United States
- University of Colorado HospitalAurora, United States
- Beth Israel Deaconess Medical CenterBoston, United States
- Massachusetts General HospitalBoston, United States
- Northwestern UniversityChicago, United States
- University of ChicagoChicago, United States
- Duke University Movement Disorders ClinicDurham, United States
- University of Florida HealthGainesville, United States
- Houston MethodistHouston, United States
- Mayo Clinic FloridaJacksonville, United States
- CNS TrialsLong Beach, United States
- UCLALos Angeles, United States
- Johns Hopkins MedicineLutherville, United States
- Columbia UniversityNew York, United States
- University of PennsylvaniaPhiladelphia, United States
- Barrow Neurological InstitutePhoenix, United States
- Northwest Neurology LtdRolling Meadows, United States
- UCSFSan Francisco, United States
- Swedish Health ServicesSeattle, United States
- University of South FloridaTampa, United States
About the trial
What the trial wants to find out
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
The 2 groups in the trial
- TroriluzoleTreatment being tested
Randomization phase (Randomization through Week 48): Participants received starting dose of troriluzole 140 milligrams (mg) capsules orally once daily for first 4 weeks, followed by 200 mg once daily for the remaining 44 weeks of 48-week duration of the double-blind randomization phase. Open-label extension (OLE) phase (OLE Week 1 up to Week 192): Participants who were eligible and agreed to enroll in an OLE phase, will receive troriluzole 200 mg capsules orally once daily for 4 weeks in a blinded manner. After OLE Week 4, all participants will then receive open label troriluzole 200 mg up to Week 192.
- PlaceboPlacebo, for comparison
Randomization phase (Randomization through Week 48): Participants received troriluzole matching placebo capsules orally once daily for 48 weeks duration of the double-blind randomization phase. OLE phase (Week 1 up to Week 192): Participants who were eligible and agreed to enroll in an OLE phase, will receive troriluzole 140 mg capsules orally once daily for the first 4 weeks in a blinded manner. After OLE Week 4, all participants will then receive open label troriluzole 200 mg up to Week 192.
Treatment: troriluzole and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.
- Publications
- Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia.Neurology and therapy, 2025
- Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis.Neurology and therapy, 2024
- Record updated
- 12 November 2026